Results 131 to 140 of about 5,907 (256)

Dulaglutide (Trulicity®), a new once-weekly agonist of Glucagon-Like Peptide-1 receptors for type 2 diabetes

, 2016
peer reviewedRésumé : Le dulaglutide (Trulicity®) est un nouvel agoniste des récepteurs du Glucagon-Like Peptide-1 (GLP-1) proposé, en injection sous-cutanée hebdomadaire, dans le traitement du diabète de type 2.
SCHEEN, André
core  

Efficacy and safety of switching to iGlarLixi from premixed insulin therapy in patients with type 2 diabetes: A real‐world experience

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Fixed‐ratio combinations such as iGlarLixi are recommended over premixed insulin as first‐line injectable therapy for type 2 diabetes mellitus (T2DM), yet real‐world evidence on transitions from premix to iGlarLixi remains limited. This study aimed to evaluate the efficacy and safety of switching from premixed insulin to iGlarLixi in a ...
Chun‐Jui Huang, Shun‐Jie Yang, Cheng‐Pin Cheng, Chun‐Hsing Lin, Ya‐Chun Lee, Harn‐Shen Chen   +5 more
wiley   +1 more source

Safety and efficacy of intermittent fasting with or without exercise in people living with overweight or obesity and type 2 diabetes—The INTERFAST‐3 study design

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Aims Lifestyle modification, including caloric restriction and exercise, is fundamental in the treatment of people living with overweight and type 2 diabetes mellitus (T2D). The overall aim of lifestyle intervention schemes is to reduce body weight and improve glycaemic control to reduce the future risk of diabetes‐associated complications ...
Caren Sourij, Alexander Müller, Abdullah Al‐Baghdadi, Faisal Aziz, Norbert J. Tripolt, Peter N. Pferschy, Eva Andritz, Harald Kojzar, Vanessa Stadlbauer, Sabrina Leal Garcia, Harald Sourij   +10 more
wiley   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

A systematic review and meta‐analysis of the relative benefit of dual versus single oral hypoglycaemic therapy following diagnosis with type 2 diabetes (T2D)

Diabetic Medicine, Volume 43, Issue 7, July 2026.
Abstract Introduction Achieving and sustaining target glycated haemoglobin (HbA1c) levels is fundamental in the management of type 2 diabetes (T2D). We here aimed to assess whether initial dual oral therapy outperforms monotherapy in reaching glycaemic targets in patients with treatment‐naive or early‐stage T2D.
Mairead Kelly, Sushant Saluja, Hugh Logan Ellis, Sarah Jamil, Martin B. Whyte, Adrian Heald   +5 more
wiley   +1 more source

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. [PDF]

Drug Des Devel Ther
Aulifa DL, Wibisono TTDW, Ningsih JD, Christy GDAB, Pertiwi DS, Praja HM, Gazzali AM, Amaliah S, Budiman A.   +8 more
europepmc   +1 more source

Cost‐Effectiveness of Control‐IQ+ Technology in Insulin‐Treated Patients With Type 2 Diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6280-6290, July 2026.
ABSTRACT Objective Automated insulin delivery (AID) has been established as an effective therapy for individuals with type 1 diabetes. This analysis evaluates the clinical and economic outcomes of AID compared with multiple daily injections plus continuous glucose monitoring (MDI/CGM) in adults with type 2 diabetes. Materials and Methods The IQVIA CORE
Neda Al Rawashdh, Bimal V. Patel, Sharon M. Wang, Richard M. Zur, Pablo Anaya, Emily B. Kahn, Jordan E. Pinsker, Ravid Sasson‐Katchalski, Alex C. Trahan, Laurel H. Messer, Kimia Assadi, Yogish C. Kudva, Roy W. Beck   +12 more
wiley   +1 more source

Targeted analysis of whole exome sequencing in Thai patients with neonatal diabetes. [PDF]

Hum Genet
Plengvidhya N, Tangjarusritaratorn T, Teerawattanapong N, Narkdontri T, Innang S, Songlilitchuwong S, Suthon S, Tangjittipokin W.   +7 more
europepmc   +1 more source

Sulfonylurea Receptors

, 2002
Joseph Bryan, Lydia Aguilar-Bryan
core   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source